Skip to main content

Table 13 Selected phase I-II clinical trials conducted with LC-161 as a single (−single-) or combined therapeutic in pre-treated or refractory (Refrac) patients with Paclitaxel (PAC), against Advanced Solid Tumor (AST) diseases (Dis.) and Outcomes for Maximum Tolerated Doses (MTD) are highlighted. Adverse effects (Adv. Effects) are highlighted as Neut (Neutropenia), Gastrointestinal symptoms (GI), Diarrhoea (Diar), Nausea (Nau), Vomiting (Vom) and Anemia (Anem). Objective Response Rates (ORR), Partial Responses (PR), Progressive Disease (PD) and disease stabilization effects (Stabil.) are highlighted as percentage (%) positive-responders. The clinical trials reference numbers highlighted in bold (left column) and their corresponding references highlighted in the columns on the right (URL/Ref). Biomarker assessments (Bio.M) are highlighted and unavailable data is highlighted by ‘-‘

From: BH3-mimetics: recent developments in cancer therapy

LCL-161

Phase

Patient

Refrac

Combined

Dis.

Outcomes

Adv. Effects

ORR

Stabil.

Bio.M

URL/Ref

NCT01240655

Ib

Pre-treated

Yes

PAC

AST

MTD

Neut/GI

27.6% PR; 25% PD

36.8%

–

www.novctrd.com

NCT01968915

I/II

–

–

-single−/

PAC

AST

–

Neut/Diar

DISC.

–

–

www.novctrd.com

NCT01098838

I/II

Pre-treated

–

-single-

AST

MTD

Naus/Vom/

Anem

0% ORR

19%

cIAP

[418]